Cytek Biosciences, Inc. — Form 8-K Summary
Reporting context: The 8-K reports an event dated September 23, 2026. Cytek Biosciences, Inc. is a Delaware corporation whose common stock trades on Nasdaq under CTKB. This is a corporate-governance filing, not a periodic financial report.
Material event
On September 23, 2026, the board unanimously adopted amended and restated bylaws, effective immediately. The full bylaws are filed as Exhibit 3.1.
- Stockholder proposal and director-nomination notices must include additional information and representations, including ownership commitments through the meeting and disclosures about proxy solicitation.
- The chairperson’s authority to disregard non-compliant nominations and proposals was expanded.
- The bylaws incorporate the universal proxy requirements under Exchange Act Rule 14a-19 and add compliance and disqualification procedures for director nominations at special meetings.
- Other changes address adjournment notices for virtual or remote meetings and the preparation and availability of the voting stockholder list under Delaware law.
Financial information and outlook
The filing provides no revenue, earnings, cash flow, margin, debt, liquidity, financial guidance, or operating outlook information. It does not report a financial comparison with a prior period.
Investor items to verify
- Review Exhibit 3.1 for the complete bylaws and the precise requirements and deadlines for stockholder nominations and proposals.
- Assess how the revised procedures and chairperson authority may affect stockholder participation and director-election processes.
The report was signed by President and Chief Executive Officer Wenbin Jiang on September 29, 2026.